Class Action Notice for Aquestive Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy AQST?
Source: Globenewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Allegations: The lawsuit claims that the company concealed critical human factors related to its New Drug Application (NDA) for Anaphylm, leading to investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Counsel Selection Advice: Rosen Law Firm emphasizes the importance of choosing qualified legal counsel with a proven track record, noting that many firms issuing notices lack the capability to handle securities class actions, urging investors to be cautious in their legal representation choices.
- Historical Performance and Reputation: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked first by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and influence in the field of securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.060
Low
6.00
Averages
9.00
High
12.00
Current: 4.060
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for participation in the lawsuit and encouraging more investors to seek legal recourse.
- Lawsuit Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and effectiveness in handling such cases.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that the important lead plaintiff deadline is May 4, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged, highlighting a lack of transparency in the company's drug development process.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, and those wishing to serve as lead plaintiffs must file with the court by May 4, 2026, ensuring their representation in the litigation.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased or acquired securities between June 16, 2025, and January 8, 2026, indicating the company faces legal risks.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension, demonstrating a commitment to client support.
- Class Action Deadline: Investors should note the deadline of May 4, 2026, to seek the role of lead plaintiff in a federal securities class action, emphasizing the time sensitivity and importance of legal proceedings.
- Potential Claim Background: This investigation suggests that Aquestive may face significant legal liabilities, which could negatively impact its stock price, prompting investors to carefully assess their investment risks.
See More
AQST Shareholder Alert: FDA Approval Delay
- Shareholder Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, to contact them regarding potential lead plaintiff status, indicating significant legal risks for the company.
- FDA Deficiency Letter: On January 9, 2026, AQST announced it received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which halted labeling discussions, directly impacting investor confidence and stock performance.
- Stock Price Plunge: Following the FDA announcement, AQST's stock price plummeted from $6.21 on January 8, 2026, to $3.91 on January 9, representing a dramatic decline of over 37% in a single day, reflecting market pessimism about the company's future.
- Lawsuit Deadline: Shareholders must register for the class action by May 4, 2026, to avoid losing their right to claim, highlighting the legal pressure on the company and the urgency for investors to act.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Allegations: The lawsuit claims that the company concealed critical human factors related to its New Drug Application (NDA) for Anaphylm, leading to investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Counsel Selection Advice: Rosen Law Firm emphasizes the importance of choosing qualified legal counsel with a proven track record, noting that many firms issuing notices lack the capability to handle securities class actions, urging investors to be cautious in their legal representation choices.
- Historical Performance and Reputation: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked first by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and influence in the field of securities litigation.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious concerns over corporate governance and compliance.
- FDA Regulatory Issues: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and indefinitely delaying approval, indicating significant challenges in the company's drug development process.
- Stock Price Plunge: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 on January 9, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, suggesting that this case could trigger broader legal and market implications.
See More
Rosen Law Firm Reminds of Aquestive Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for participation in the lawsuit and encouraging more investors to seek legal recourse.
- Lawsuit Background: The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application, failing to disclose critical human factors in the use of its sublingual film, which resulted in investor losses when the truth emerged, highlighting significant issues in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and effectiveness in handling such cases.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that the important lead plaintiff deadline is May 4, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements and failed to disclose the true state of the New Drug Application (NDA) for Anaphylm, resulting in investor losses when the truth emerged, highlighting a lack of transparency in the company's drug development process.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Participation Instructions: Investors can join the class action by visiting Rosen Law Firm's website or calling toll-free at 866-767-3653, and those wishing to serve as lead plaintiffs must file with the court by May 4, 2026, ensuring their representation in the litigation.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against Aquestive Therapeutics, Inc., particularly for investors who purchased or acquired securities between June 16, 2025, and January 8, 2026, indicating the company faces legal risks.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing phone numbers and extension, demonstrating a commitment to client support.
- Class Action Deadline: Investors should note the deadline of May 4, 2026, to seek the role of lead plaintiff in a federal securities class action, emphasizing the time sensitivity and importance of legal proceedings.
- Potential Claim Background: This investigation suggests that Aquestive may face significant legal liabilities, which could negatively impact its stock price, prompting investors to carefully assess their investment risks.
See More
AQST Shareholder Alert: FDA Approval Delay
- Shareholder Notice: The Gross Law Firm has issued a notice encouraging shareholders who purchased AQST shares between June 16, 2025, and January 8, 2026, to contact them regarding potential lead plaintiff status, indicating significant legal risks for the company.
- FDA Deficiency Letter: On January 9, 2026, AQST announced it received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, which halted labeling discussions, directly impacting investor confidence and stock performance.
- Stock Price Plunge: Following the FDA announcement, AQST's stock price plummeted from $6.21 on January 8, 2026, to $3.91 on January 9, representing a dramatic decline of over 37% in a single day, reflecting market pessimism about the company's future.
- Lawsuit Deadline: Shareholders must register for the class action by May 4, 2026, to avoid losing their right to claim, highlighting the legal pressure on the company and the urgency for investors to act.
See More
Class Action Notice for Aquestive Therapeutics Investors
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Allegations: The lawsuit claims that the company concealed critical human factors related to its New Drug Application (NDA) for Anaphylm, leading to investor losses when the truth emerged, highlighting significant failures in the company's disclosure practices.
- Legal Counsel Selection Advice: Rosen Law Firm emphasizes the importance of choosing qualified legal counsel with a proven track record, noting that many firms issuing notices lack the capability to handle securities class actions, urging investors to be cautious in their legal representation choices.
- Historical Performance and Reputation: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked first by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and influence in the field of securities litigation.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has filed a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious concerns over corporate governance and compliance.
- FDA Regulatory Issues: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and indefinitely delaying approval, indicating significant challenges in the company's drug development process.
- Stock Price Plunge: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 on January 9, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, suggesting that this case could trigger broader legal and market implications.
See More
